DV
Dividend Vision

LADX — LadRx Corporation

LadRx Corporation (LADX)

Its deepest 1-year drawdown was 99.9%.

LadRx Corporation is a biopharmaceutical company developing chemotherapeutic drugs for solid tumors using its linker activated drug releases (LADR) technology platform, which delivers chemotoxic agents directly to tumor environments. The company's lead candidates include novel LADR derivatives targeting various tumors and aldoxorubicin in phase II development for pancreatic cancer treatment, along with a companion diagnostic tool. LadRx does not currently distribute dividends.

LADX key facts

Asset type
Stock
Asset class
Equity
Last close
$0.01
Market cap
$49,509
Average volume
0.0
Ex-dividend date
03/07/2008
Payment date
11/01/2017
Beta
1.314
Payout ratio
0.0
Forward P/E
13.986
EPS
$-5.04